EFFICACY COMPARISON OF TRANSARTERIAL CHEMOINFUSION WITH DOXORUBICIN AND CISPLATIN IN INTERMEDIATE HEPATOCELLULAR CARCINOMA

Hepatocellular Carcinoma (HCC) is the most common type of primary liver neoplasm and is the third cause of cancer death worldwide. In HCC that cannot be resected, transarterial chemoinfusion (TACI) is one of the therapies of choice. The aim of this study was to compare the efficacy measured by mRECIST, Child-Turcotte-Pugh (CTP), and Alfa-FetoProtein (AFP) in patients with intermediate-stage hepatocellular carcinoma (HCC) undergoing transarterial chemoinfusion (TACI) using Doxorubicin and Cisplatin. Samples were collected over a period of 3 years from January 2021 to December 2023 at our center. Univariate analysis was carried out to describe sample characteristic and bivariate analysis using the Kruskal-Wallis test was used to compare the efficacy of the two drugs. There are 60 subject that met the inclusion criteria, of which 32 samples underwent TACI with cisplatin and 28 samples underwent TACI with doxorubicin. Our subject were mostly male (85%), age 46-55 years (45%), and Hepatitis B (48.8%). Comparison of TACI with cisplatin and TACI with doxorubicin in each cycle from 1st cycle to 5th cycle in terms of CTP, and AFP found no significant differences (P= >0.005) but in terms of mRECIST there are significance differences (P= 0.015) in the 3rd TACI cycle. Using mRECIST criteria, TACI doxorubicin has significantly higher rate of partial response than stable disease compared to TACI cisplatin on the 3rd TACI cycle. However final decision on regiment should also consider nephrotoxicity and cardiotoxicity to suit each subject comorbidity.